Tong-Xie-Yao-Fang Regulates 5-HT Level in Diarrhea Predominant Irritable Bowel Syndrome Through Gut Microbiota Modulation
Tong-Xie-Yao-Fang (TXYF) has been widely used for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in traditional Chinese medicine. However, its mechanism of action in the treatment of IBS-D remains to be fully understood. Recent reports have shown that species in the gut can i...
Saved in:
Published in | Frontiers in pharmacology Vol. 9; p. 1110 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Switzerland
Frontiers Media S.A
28.09.2018
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Tong-Xie-Yao-Fang (TXYF) has been widely used for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in traditional Chinese medicine. However, its mechanism of action in the treatment of IBS-D remains to be fully understood. Recent reports have shown that
species in the gut can induce
production in the colon, which then contributes to IBS-D. Due to the wide use of TXYF in the clinical treatment of IBS-D and the close relationship between gut microbiota and IBS-D, we hypothesize that TXYF treats IBS-D by modulating gut microbiota and regulating colonic
levels. In this study, variation analysis of 16S rRNA was conducted to evaluate changes in the distribution of gut microbiota in IBS-D model rats after TXYF treatment. Moreover, we investigated whether TXYF could affect colonic
levels in IBS-D model rats. We then performed fecal transplantation experiments to confirm the effects of TXYF on gut microbiota and
levels. We found that TXYF treatment can ameliorate IBS-D and regulate
levels in colon tissue homogenates. TXYF treatment also affected the diversity of gut microbiota and altered the relative abundance of
and
in gut flora populations. Finally, we showed that fecal transplantation from TXYF-treated rats could relieve IBS-D and regulate
levels in colon tissue homogenates. In conclusion, the present study demonstrates that TXYF treatment diminishes colonic
levels and alleviates the symptoms of IBS-D by favorably affecting microbiota levels in gut flora communities. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology Reviewed by: Fangyan Wang, Wenzhou Medical University, China; Fernando Ochoa-Cortes, Universidad Autónoma de San Luis Potosí, Mexico; Michael T. Bailey, The Ohio State University College of Medicine, United States Edited by: Benedict Green, Agricultural Research Service (USDA), United States |
ISSN: | 1663-9812 1663-9812 |
DOI: | 10.3389/fphar.2018.01110 |